Two separate things are happening with morphine sulfate right now, and mixing them up leads people to either panic unnecessarily or miss something they should actually check. One is a specific, single-lot recall tied to a labeling error. The other is a slower, ongoing supply squeeze that has nothing to do with that recall. This guide walks through both, in order, so you know exactly what applies to your situation.
1. The August 2026 Recall: What Happened
Fresenius Kabi, part of the Fresenius Group, announced a voluntary nationwide recall on August 4, 2026, for one lot of Morphine Sulfate Injection, USP, sold under its Simplist prefilled syringe line at a 2 mg/1 mL strength. The problem was a label mix-up: some MicroVault packaging units printed as morphine 2 mg/1 mL were instead found to contain a prefilled syringe of Dilaudid (hydromorphone HCl) 0.5 mg/0.5 mL.
Why this matters: hydromorphone is roughly five to ten times more potent than morphine on a milligram-to-milligram basis. A patient or clinician expecting a standard morphine dose who instead receives hydromorphone from a mislabeled unit could face a significant overdose, with life-threatening respiratory depression as the primary risk. Patients who don't use opioids regularly, those with underlying respiratory conditions, children, and anyone also taking a central nervous system depressant are at the highest risk.
The recalled lot number is 6402813. The product was distributed nationwide to distributors and wholesalers, which supply hospitals, hospices, surgical centers, and home infusion pharmacies rather than typical retail pharmacies. Fresenius Kabi is notifying its direct customers and arranging for return of the affected units, and the recall is being conducted down to the individual user level, meaning facilities and caregivers are expected to check units directly rather than assume the issue was caught upstream.
As of this update, Fresenius Kabi has not confirmed any adverse events connected to this recall. That's a reassuring detail, but it doesn't reduce the importance of checking your own supply if you or someone you care for receives morphine sulfate injection at home, in hospice, or in a clinical setting.
2. Is Morphine Also in a Shortage?
Yes, and this is genuinely separate from the recall above. Multiple morphine formulations are currently listed on both the FDA's Drug Shortages Database and the ASHP Drug Shortage Resource Center: morphine oral solution, extended-release tablets, immediate-release tablets, and several injectable concentrations. This is unlike some other commonly searched "shortage" topics where the FDA list is actually clear. With morphine, the listings are real and current.
This distinction matters because the recall is narrow (a single lot, a single strength, a single manufacturer) while the shortage is broad (multiple formulations, multiple manufacturers, ongoing allocation and back-order status). You could be completely unaffected by the recall and still run into a wall trying to fill a routine morphine prescription because of the separate shortage.
3. Timeline: Morphine Supply and Recalls
| Date | Event |
|---|---|
| February 2025 | Sun Pharma recalls roughly 10,000 bottles of 100 mg morphine sulfate extended-release tablets nationwide after the product failed FDA dissolution testing specifications |
| 2025 | Morphine oral solution supply tightens; Hikma begins allocating several bottle sizes |
| 2025 | Several manufacturers, including Major, discontinue specific morphine ER tablet strengths and unit-dose packaging formats |
| Late 2025 | FDA adds morphine tablets and injectable morphine solutions to its official shortage list, citing discontinuations and short supply |
| January 2026 | DEA sets 2026 opioid production quotas, raising the morphine quota while cutting oxycodone and hydrocodone quotas, a decision made partly in response to the FDA shortage listing |
| Early–mid 2026 | Morphine IR tablets, oral solution, and injectable concentrations remain on allocation or back order at Hikma and Pfizer, with rolling estimated release dates |
| August 4–5, 2026 | Fresenius Kabi recalls one lot (6402813) of Simplist morphine sulfate injection 2 mg/1 mL due to a label mix-up with Dilaudid |
4. Current Availability by Product
| Product / Form | Manufacturer | Status |
|---|---|---|
| Morphine oral solution, various concentrations | Hikma | On allocation; 120 mL bottles on back order |
| Morphine ER tablets (most strengths) | Rhodes | Generally available |
| Morphine ER tablets, several strengths | Major, Sun Pharma, Teva | Specific NDCs discontinued at certain strengths |
| Morphine IR tablets, 15 mg / 30 mg | Hikma | On allocation |
| Morphine injection, 2–10 mg/mL syringes | Hikma, Pfizer | On allocation or back order; limited weekly releases |
| Morphine Sulfate Injection Simplist 2 mg/1 mL, lot 6402813 | Fresenius Kabi | Recalled; other lots and strengths unaffected |
Notice that "on allocation" doesn't mean unavailable everywhere. It means a manufacturer is rationing shipments across its existing customers rather than filling every order in full. A hospice pharmacy or hospital that already has an account with an unaffected supplier may see no disruption at all, while a smaller facility further down the allocation list waits longer.
5. Why Morphine Keeps Running Short
The core driver is the DEA's Aggregate Production Quota system. Each year, the DEA decides how much raw opioid material every manufacturer is allowed to procure and convert into finished drug product. That quota is set independently of how many prescriptions doctors are actually writing, which means a real clinical need can outpace what manufacturers are permitted to produce.
For 2026, the DEA made an unusual move: it raised the morphine quota specifically after the FDA added morphine tablets and injectable solutions to its shortage list, while cutting quotas for oxycodone and hydrocodone at the same time. The agency has publicly stated that shortages themselves aren't its responsibility, pointing instead to manufacturing problems, processing delays, and discontinuations, even though its own quota decisions shape how much room manufacturers have to respond to those problems.
On top of the quota system, several manufacturers have simply stopped making specific strengths or package sizes of morphine tablets. Low-volume, low-margin generic strengths are often the first to go when a company reviews its product line, which leaves gaps that don't line up neatly with how commonly a given strength is prescribed.
6. Safety Check: If You Have the Recalled Lot
If you or someone you care for receives morphine sulfate injection at home, in hospice, or through a home infusion pharmacy, do this before anything else.
- Check the lot number. Look at the MicroVault or syringe packaging for lot 6402813. If your supply doesn't match, you're not affected by this specific recall.
- If it matches, stop using it and contact your supplying pharmacy or hospice team immediately for return instructions. Don't administer or discard it yourself.
- If a dose from a suspect syringe was already given, watch closely for signs of an opioid overdose: unusual drowsiness beyond what's expected, slow or shallow breathing, blue-tinged lips or fingertips, or unresponsiveness.
- Call 911 immediately if you see any of these signs, and use naloxone (Narcan) right away if it's on hand while you wait for emergency responders.
Example: a home hospice patient receiving scheduled morphine injections through a visiting nurse should ask that nurse to confirm the lot number on the next visit rather than waiting for a mailed notice, since hospice supply often comes in small batches that could include the affected lot without anyone realizing it yet.
7. Alternatives If Morphine Isn't Available
If your specific strength or formulation of morphine is genuinely unavailable, and your pharmacist can't source it from a different manufacturer, your prescriber may consider another opioid. These are the ones most commonly discussed as alternatives, with important caveats.
| Alternative | Typical use | Key consideration |
|---|---|---|
| Oxycodone | Moderate to severe pain, oral formulations | Also affected by DEA quota changes; supply varies by manufacturer |
| Hydromorphone (Dilaudid) | Severe pain, oral and injectable | Considerably more potent per mg than morphine; requires careful, prescriber-directed dosing |
| Fentanyl patch | Chronic, stable pain in opioid-tolerant patients only | Not appropriate for acute pain or opioid-naive patients |
| Methadone | Chronic pain management, specialist-directed | Long, variable half-life; accumulation risk requires close monitoring |
A short-term opioid switch can make sense when...
- Your prescriber has confirmed no unaffected morphine supply is reachable in time
- The alternative is appropriate for your specific type and severity of pain
- Dosing is calculated and written by your prescriber, not estimated at home
It's worth avoiding when...
- You still have a few days of your current supply and haven't yet called other pharmacies
- You're opioid-naive and the alternative under discussion is meant for tolerant patients, like a fentanyl patch
- No one has confirmed insurance or hospice coverage for the new medication yet
8. Switching Opioids Safely
Opioids are not interchangeable milligram-for-milligram. Converting from one opioid to another requires a validated calculation that accounts for tolerance, kidney and liver function, and the specific formulation involved. There's no universally accepted conversion factor even among clinicians, which is exactly why this recall is dangerous: a labeling error silently swapped one opioid for a much stronger one with no calculation at all. Never estimate a dose change yourself, and never assume two opioid products are equivalent just because the printed strength looks similar.
Stopping a long-term opioid abruptly, or going without a scheduled dose in hospice or cancer pain management, can also cause withdrawal symptoms: sweating, gastrointestinal distress, anxiety, and a flare in the underlying pain being treated. This is a separate risk from the overdose concern above, but it's a real reason to contact your care team early rather than waiting until you're completely out.
9. Step-by-Step: What to Do If You're Out
Check the recall lot number first
Rule out lot 6402813 before doing anything else if you use injectable morphine at home or through hospice.
Call your pharmacy or hospice team about your specific product
Ask whether your exact strength and formulation are affected by the broader shortage, and whether they can source it from a manufacturer that isn't on allocation.
Ask about therapeutically equivalent stock
A different manufacturer's version of the same strength and release profile is usually a simple swap that doesn't require a new prescription.
Insist on a written plan if a formulation change is needed
If your prescriber needs to switch you to a different opioid or a different release formulation of morphine, ask for the specific dosing plan in writing rather than a verbal estimate.
Never ration or stretch doses on your own
Contact your prescriber or hospice nurse the same day if you're at real risk of running out, especially in hospice or cancer pain settings where consistent pain control matters most.
10. What Morphine Costs in 2026
Generic morphine is one of the least expensive opioids on the market, which is part of why the 2026 story is about availability, not affordability.
- Oral immediate-release and extended-release tablets: typically $10 to $60 for a month's supply at a standard dose, without insurance.
- Oral solution: generally low-cost as well, though pricing varies more by concentration and bottle size.
- With a free discount card, compared in our Inside Rx vs SingleCare comparison, retail cash prices drop further at most major pharmacy chains.
- Hospice and home infusion morphine is usually billed differently. Under the Medicare Hospice Benefit, medications tied to a patient's terminal diagnosis are typically bundled into the hospice per-diem payment rather than charged separately, so most hospice patients see little to no direct cost for their morphine.
- Manufacturer copay cards, the kind common for expensive brand-name drugs, generally don't apply to generic morphine since there's no brand product driving the price up in the first place.
Before assuming cost is your issue, use a drug price checker to compare pharmacies near you. It's rarely the price that stalls a morphine fill in 2026, it's whether a given pharmacy or supplier has your exact strength in stock.
11. Comparing Access and Assistance Options
Because morphine is cheap as a generic, most outpatient patients won't need a formal patient assistance program. Where people get tripped up is Medicare Part D opioid safety edits and hospice billing questions. Here's how the main options compare.
Eligibility Comparison
| Option | Who qualifies |
|---|---|
| Free discount cards (GoodRx, Inside Rx, SingleCare) | Anyone with a valid outpatient prescription — no income requirement |
| Medicare Hospice Benefit | Medicare beneficiaries certified as terminally ill with a prognosis of six months or less, enrolled with a Medicare-certified hospice |
| Medicare Extra Help (Low-Income Subsidy) | Part D enrollees who meet income and asset limits |
| NeedyMeds / state pharmaceutical assistance | Varies by program; typically income-based, searchable by drug and state |
Income Limit Comparison
| Option | General income guideline |
|---|---|
| Discount cards | No income limit |
| Medicare Hospice Benefit | Based on Medicare eligibility and hospice certification, not income |
| Medicare Extra Help | Updated annually by the Social Security Administration; confirm current limits at Medicare.gov before assuming you don't qualify |
| NeedyMeds programs | Varies widely; searchable at NeedyMeds or BenefitsCheckUp |
Covered Medications Comparison
| Option | Covers outpatient morphine? | Covers hospice/injectable morphine? |
|---|---|---|
| Discount cards | Yes | No — retail cash prices only |
| Medicare Hospice Benefit | Not applicable outside hospice | Yes, bundled into the hospice per-diem |
| Medicare Extra Help | Yes, lowers Part D copays | Only if billed through Part D rather than the hospice benefit |
Application, Approval, and Renewal
| Option | How to apply | Typical approval time | Renewal |
|---|---|---|---|
| Discount cards | Show a code or app at the register — no application | Instant | None needed |
| Medicare Hospice Benefit | Hospice agency and physician jointly certify terminal prognosis | Often within days | Recertified at defined benefit periods as care continues |
| Medicare Extra Help | Apply through the Social Security Administration or Medicare.gov | 4 to 6 weeks | Annual review; some beneficiaries are auto-renewed |
| Part D prior authorization for high-dose opioids | Prescriber submits documentation to the plan | Typically 24 to 72 hours; longer if appealed | Often required again at each new prescription or dose change |
Common Mistakes to Avoid
- Assuming hospice patients pay retail price for morphine. Medications tied to the terminal diagnosis are usually covered under the hospice per-diem, not billed separately.
- Not asking the hospice team about a backup supply when a pharmacy reports a shortage. Hospice pharmacies often have arrangements with multiple suppliers that patients aren't aware of.
- Assuming a manufacturer savings card exists for generic morphine. These programs are built for expensive brand-name drugs; there's rarely a comparable card for a low-cost generic opioid.
- Not anticipating a Part D prior authorization requirement. Many plans require prior authorization or have quantity limits above certain opioid dose thresholds; see our Medicare Part D changes guide for what's different this year.
- Waiting until the pharmacy counter to raise a shortage issue. Calling ahead gives a pharmacist time to check alternate manufacturers or flag a prior authorization need before you're standing there without medication.
12. Decision Tree: What to Do Right Now
Ask about a bridge supply or a short-term alternative rather than stopping or rationing your morphine without a plan.
Related: Adderall Shortage 2026: Pharmacy Availability & Alternatives
Another controlled substance where DEA production quotas play a bigger role in local stockouts than a true national shortage.
Need help with prescription costs or coverage questions?